SYNTHESIS AND DISTRIBUTION OF OPIOID & RELATED PEPTIDES

阿片类药物的合成和分配

• 批准号: 2420220
• 负责人: Richard Allen Houghten
• 金额: $ 45.22万
• 依托单位: MIXTURE SCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-08-01 至 2001-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2420220
• 关键词: chemical synthesis; drug design /synthesis /production; drug quality /standard; endogenous opioid; radiotracer

For nearly two decades, the National Institute on Drug Abuse and it's predecessor, Center for Studies of Narcotics and Drug Abuse, NIMH, has provided the scientific community working on problems of drug abuse with authentic, standardized supplies of controlled research drugs and chemicals. These include marijuana cigarettes, known hallucinogens, heroin, amphetamines, cannabinoids, and many other drugs essential for both clinical and laboratory -research studies. Recently, the isolation of Leu5-enkephalin, Met5-enkephalin, and other opioid peptides has generated an explosive interest in this research area. This active research area has generated the need for several opioid peptides and respective radiolabeled compounds in large guantities. The peptides are needed for a number of preclinical and clinical studies supported by NIDA--receptor-binding studies, evaluation of addiction and analgetic potential, pharmacokinetic studies, conformational studies by C.D.; N.M.R.; X-ray, laser-Raman, FT-IR, etc. Opioid peptides and their respective radiolabeled compounds are expensive and purity is not always sufficiently established. In order to meet the demand for pure, authentic compounds, NIDA plans to continue to maintain an inventory of about 10-15 peptides and their respective radiolabeled compounds for use in NIDA supported studies. Through this contract NIDA plans to continue to supply chemically pure, racemization-free peptides primarily to NIDA grantees and at the same time maintain capability to rapidly synthesize, on demand, new compounds that are potentially useful.

近二十年来，国家药物滥用研究所及其 其前身是麻醉品和药物滥用研究中心，NIMH， 为研究药物滥用问题的科学界提供了 真实的、标准化的受控研究药物供应， 化学品 其中包括大麻香烟，已知的致幻剂， 海洛因、安非他明、大麻素和许多其他药物， 临床和实验室研究。 最近，隔离 Leu5-脑啡肽，Met5-脑啡肽和其他阿片肽的合成 引起了人们对这一研究领域的极大兴趣。 此active 研究领域已经产生了对几种阿片肽的需求， 各自的放射性标记的化合物在大的量。 所述肽 支持的大量临床前和临床研究所需 NIDA-受体结合研究，成瘾和戒毒的评价 C.D.进行的潜在、药代动力学研究、构象研究; N.M.R.; X射线、激光拉曼、红外光谱等。 各个放射性标记的化合物是昂贵的并且纯度并不总是 充分确立。 为了满足纯净的需求， 真正的化合物，NIDA计划继续保持库存 约10 - 15种肽和它们各自的放射性标记化合物 NIDA支持的研究。 通过这份合同，NIDA计划继续 主要向NIDA提供化学纯、无外消旋化的肽 同时保持快速综合的能力， 根据需要，可能有用的新化合物。